InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,018.08
(
-1.06%
)
US TECH 100
16,823.20
(
-1.39%
)
Dow Jones
37,902.24
(
-1.45%
)
Brent Oil
86.75
(
-0.54%
)
Bitcoin
64,021.63
(
-0.40%
)
Post# of 220675
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

12yearplan

Send PM Follow Ignore
Followers 142
Posts 22177
Boards Moderated 2
Alias Born 02/01/2013

12yearplan

Member Level

Re: janice shell post# 160011

Monday, 10/14/2019 7:53:47 PM

Monday, October 14, 2019 7:53:47 PM

Post# of 220675
What if pharma companies could avoid the costs, logistical effort, and regulatory hurdles altogether by developing synthetic cannabinoids? Would pharmaceuticals containing chemically synthesized CBD have a better shot at FDA approval than those derived from the federally illegal cannabis plant?
What is synthetic CBD?

...

 McCoy reported that Noramco’s CEO, James Mish, told the audience he sees the market for CBD splitting into two with plant-derived CBD and THC serving the recreational and nutraceutical market, and synthetic CBD and THC dominating the pharmaceutical market.
 https://www.cardiolrx.com/is-synthetic-cbd-the-future-of-cannabis-pharma/

https://www.noramco.com/#
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up